Identification of Small-Molecule Inhibitors of Fibroblast Growth Factor 23 Signaling via In Silico Hot Spot Prediction and Molecular Docking to α-Klotho

Fibroblast growth factor 23 (FGF23) is a therapeutic target for treating hereditary and acquired hypophosphatemic disorders, such as X-linked hypophosphatemic (XLH) rickets and tumor-induced osteomalacia (TIO), respectively. FGF23-induced hypophosphatemia is mediated by signaling through a ternary complex formed by FGF23, the FGF receptor (FGFR), and α-Klotho. Currently, disorders of excess FGF23 are treated with an FGF23-blocking antibody, burosumab. Small-molecule drugs that disrupt protein/protein interactions necessary for the ternary complex formation offer an alternative to disrupting FGF23 signaling. In this study, the FGF23:α-Klotho interface was targeted to identify small-molecule protein/protein interaction inhibitors since it was computationally predicted to have a large fraction of hot spots and two druggable residues on α-Klotho. We further identified Tyr433 on the KL1 domain of α-Klotho as a promising hot spot and α-Klotho as an appropriate drug-binding target at this interface. Subsequently, we performed in silico docking of ∼5.5 million compounds from the ZINC database to the interface region of α-Klotho from the ternary crystal structure. Following docking, 24 and 20 compounds were in the final list based on the lowest binding free energies to α-Klotho and the largest number of contacts with Tyr433, respectively. Five compounds were assessed experimentally by their FGF23-mediated extracellular signal-regulated kinase (ERK) activities in vitro, and two of these reduced activities significantly. Both these compounds were predicted to have favorable binding affinities to α-Klotho but not have a large number of contacts with the hot spot Tyr433. ZINC12409120 was found experimentally to disrupt FGF23:α-Klotho interaction to reduce FGF23-mediated ERK activities by 70% and have a half maximal inhibitory concentration (IC50) of 5.0 ± 0.23 μM. Molecular dynamics (MD) simulations of the ZINC12409120:α-Klotho complex starting from in silico docking poses reveal that the ligand exhibits contacts with residues on the KL1 domain, the KL1-KL2 linker, and the KL2 domain of α-Klotho simultaneously, thereby possibly disrupting the regular function of α-Klotho and impeding FGF23:α-Klotho interaction. ZINC12409120 is a candidate for lead optimization.

[1]  K. White,et al.  Identification of a second Klotho interaction site in the C terminus of FGF23. , 2021, Cell reports.

[2]  I. Lax,et al.  FGF23 contains two distinct high-affinity binding sites enabling bivalent interactions with α-Klotho , 2020, Proceedings of the National Academy of Sciences.

[3]  L. Darryl Quarles,et al.  Design and development of FGF-23 antagonists: Definition of the pharmacophore and initial structure-activity relationships probed by synthetic analogues. , 2020, Bioorganic & medicinal chemistry.

[4]  Duncan Poole,et al.  Supercomputer-Based Ensemble Docking Drug Discovery Pipeline with Application to Covid-19 , 2020, J. Chem. Inf. Model..

[5]  P. Arango Sancho.  Complications of Phosphate and Vitamin D Treatment in X-Linked Hypophosphataemia , 2020, Advances in Therapy.

[6]  M. Chammas,et al.  Nephrocalcinosis and Nephrolithiasis in X-Linked Hypophosphatemic Rickets: Diagnostic Imaging and Risk Factors , 2019, Journal of the Endocrine Society.

[7]  John J. M. Wiener,et al.  Accelerating Lead Identification by High Throughput Virtual Screening: Prospective Case Studies from the Pharmaceutical Industry , 2019, J. Chem. Inf. Model..

[8]  Yurii S. Moroz,et al.  Ultra-large library docking for discovering new chemotypes , 2019, Nature.

[9]  Yan Li,et al.  Comparative Assessment of Scoring Functions: The CASF-2016 Update , 2018, J. Chem. Inf. Model..

[10]  Hao Wang,et al.  Enhanced Prediction of Hot Spots at Protein-Protein Interfaces Using Extreme Gradient Boosting , 2018, Scientific Reports.

[11]  Stephani Joy Y Macalino,et al.  Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery , 2018, Molecules.

[12]  Thomas Gaillard,et al.  Evaluation of AutoDock and AutoDock Vina on the CASF-2013 Benchmark , 2018, J. Chem. Inf. Model..

[13]  Jason E Gestwicki,et al.  Inhibitors of protein-protein interactions (PPIs): an analysis of scaffold choices and buried surface area. , 2018, Current opinion in chemical biology.

[14]  Wei Tian,et al.  CASTp 3.0: computed atlas of surface topography of proteins , 2018, Nucleic Acids Res..

[15]  Bentley M Wingert,et al.  Improving small molecule virtual screening strategies for the next generation of therapeutics. , 2018, Current opinion in chemical biology.

[16]  Rommie E. Amaro,et al.  Ensemble Docking in Drug Discovery. , 2018, Biophysical journal.

[17]  J. S. San Martin,et al.  Burosumab Therapy in Children with X‐Linked Hypophosphatemia , 2018, The New England journal of medicine.

[18]  Yvette N. Lamb.  Burosumab: First Global Approval , 2018, Drugs.

[19]  Gianni De Fabritiis,et al.  KDEEP: Protein-Ligand Absolute Binding Affinity Prediction via 3D-Convolutional Neural Networks , 2018, J. Chem. Inf. Model..

[20]  M. Mohammadi,et al.  αKlotho is a Non-Enzymatic Molecular Scaffold for FGF23 Hormone Signaling , 2018, Nature.

[21]  R. Dror,et al.  D4 dopamine receptor high-resolution structures enable the discovery of selective agonists , 2017, Science.

[22]  A. Molinolo,et al.  Tumor-induced osteomalacia , 2017, Bone reports.

[23]  Vishal C. Kalel,et al.  Inhibitors of PEX14 disrupt protein import into glycosomes and kill Trypanosoma parasites , 2017, Science.

[24]  Jeremy C. Smith,et al.  A computationally identified compound antagonizes excess FGF-23 signaling in renal tubules and a mouse model of hypophosphatemia , 2016, Science Signaling.

[25]  B. L. de Groot,et al.  CHARMM36m: an improved force field for folded and intrinsically disordered proteins , 2016, Nature Methods.

[26]  Ben M. Webb,et al.  Comparative Protein Structure Modeling Using MODELLER , 2016, Current protocols in bioinformatics.

[27]  Junfeng Xia,et al.  Predicting hot spots in protein interfaces based on protrusion index, pseudo hydrophobicity and electron-ion interaction pseudopotential features , 2016, Oncotarget.

[28]  Berk Hess,et al.  GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers , 2015 .

[29]  F. Glorieux,et al.  Pharmacokinetics and pharmacodynamics of a human monoclonal anti‐FGF23 antibody (KRN23) in the first multiple ascending‐dose trial treating adults with X‐linked hypophosphatemia , 2015, Journal of clinical pharmacology.

[30]  Douglas E. V. Pires,et al.  pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures , 2015, Journal of medicinal chemistry.

[31]  Dima Kozakov,et al.  The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins , 2015, Nature Protocols.

[32]  Sally R. Ellingson,et al.  Multi-conformer ensemble docking to difficult protein targets. , 2015, The journal of physical chemistry. B.

[33]  Renxiao Wang,et al.  Comparative Assessment of Scoring Functions on an Updated Benchmark: 1. Compilation of the Test Set , 2014, J. Chem. Inf. Model..

[34]  S. Fukumoto.  Diagnostic Modalities for FGF23-Producing Tumors in Patients with Tumor-Induced Osteomalacia , 2014, Endocrinology and metabolism.

[35]  M. Peacock,et al.  Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. , 2014, The Journal of clinical investigation.

[36]  Sally R. Ellingson,et al.  VinaMPI: Facilitating multiple receptor high‐throughput virtual docking on high‐performance computers , 2013, J. Comput. Chem..

[37]  Shuigeng Zhou,et al.  Boosting Prediction Performance of Protein-Protein Interaction Hot Spots by Using Structural Neighborhood Properties - (Extended Abstract) , 2013, RECOMB.

[38]  Alexander D. MacKerell,et al.  Extension of the CHARMM general force field to sulfonyl‐containing compounds and its utility in biomolecular simulations , 2012, J. Comput. Chem..

[39]  Alexander D. MacKerell,et al.  Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone φ, ψ and side-chain χ(1) and χ(2) dihedral angles. , 2012, Journal of chemical theory and computation.

[40]  Ryan G. Coleman,et al.  ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..

[41]  Roman A. Laskowski,et al.  LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery , 2011, J. Chem. Inf. Model..

[42]  Julie C. Mitchell,et al.  KFC2: A knowledge‐based hot spot prediction method based on interface solvation, atomic density, and plasticity features , 2011, Proteins.

[43]  C. Sima,et al.  Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design , 2011, Clinical Cancer Research.

[44]  L. Quarles,et al.  The bone and beyond: 'Dem bones' are made for more than walking , 2011, Nature Medicine.

[45]  Xing-Ming Zhao,et al.  APIS: accurate prediction of hot spots in protein interfaces by combining protrusion index with solvent accessibility , 2010, BMC Bioinformatics.

[46]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[47]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[48]  Alexander D. MacKerell,et al.  CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields , 2009, J. Comput. Chem..

[49]  A. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[50]  Doheon Lee,et al.  A feature-based approach to modeling protein–protein interaction hot spots , 2009, Nucleic acids research.

[51]  Julie C. Mitchell,et al.  An automated decision‐tree approach to predicting protein interaction hot spots , 2007, Proteins.

[52]  S. Kliewer,et al.  Molecular Insights into the Klotho-Dependent, Endocrine Mode of Action of Fibroblast Growth Factor 19 Subfamily Members , 2007, Molecular and Cellular Biology.

[53]  K. Okawa,et al.  Klotho converts canonical FGF receptor into a specific receptor for FGF23 , 2006, Nature.

[54]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[55]  L. Quarles,et al.  Evidence for a bone-kidney axis regulating phosphate homeostasis. , 2003, The Journal of clinical investigation.

[56]  L. Quarles,et al.  Serum FGF23 Levels in Normal and Disordered Phosphorus Homeostasis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[57]  T. Kortemme,et al.  A simple physical model for binding energy hot spots in protein–protein complexes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[58]  R. Lefkowitz,et al.  Epidermal Growth Factor (EGF) Receptor-dependent ERK Activation by G Protein-coupled Receptors , 2001, The Journal of Biological Chemistry.

[59]  Tudor I. Oprea,et al.  The Design of Leadlike Combinatorial Libraries. , 1999, Angewandte Chemie.

[60]  X. Daura,et al.  Peptide Folding: When Simulation Meets Experiment , 1999 .

[61]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[62]  Ernst P. Mücke,et al.  Three-dimensional alpha shapes , 1994, TOGS.

[63]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[64]  Loukas Petridis,et al.  Novel Small Molecule Fibroblast Growth Factor 23 Inhibitors Increase Serum Phosphate and Improve Skeletal Abnormalities in Hyp Mice S , 2022 .